Unknown

Dataset Information

0

Development of novel anilinoquinazoline-based carboxylic acids as non-classical carbonic anhydrase IX and XII inhibitors.


ABSTRACT: As part of our ongoing endeavour to identify novel inhibitors of cancer-associated CA isoforms IX and XII as possible anticancer candidates, here we describe the design and synthesis of small library of 2-aryl-quinazolin-4-yl aminobenzoic acid derivatives (6a-c, 7a-c, and 8a-c) as new non-classical CA inhibitors. On account of its significance in the anticancer drug discovery and in the development of effective CAIs, the 4-anilinoquinazoline privileged scaffold was exploited in this study. Thereafter, the free carboxylic acid functionality was appended in the ortho (6a-c), meta (7a-c), or para-positon (8a-c) of the anilino motif to furnish the target inhibitors. All compounds were assessed for their inhibitory activities against the hCA I, II (cytosolic), IX, and XII (trans-membrane, tumour-associated) isoforms. Moreover, six quinazolines (6a-c, 7b, and 8a-b) were chosen by the NCI-USA for in vitro anti-proliferative activity evaluation against 59 human cancer cell lines representing nine tumour subpanels.

SUBMITTER: Elsayed ZM 

PROVIDER: S-EPMC10035947 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of novel anilinoquinazoline-based carboxylic acids as non-classical carbonic anhydrase IX and XII inhibitors.

Elsayed Zainab M ZM   Almahli Hadia H   Nocentini Alessio A   Ammara Andrea A   Supuran Claudiu T CT   Eldehna Wagdy M WM   Abou-Seri Sahar M SM  

Journal of enzyme inhibition and medicinal chemistry 20231201 1


As part of our ongoing endeavour to identify novel inhibitors of cancer-associated CA isoforms IX and XII as possible anticancer candidates, here we describe the design and synthesis of small library of 2-aryl-quinazolin-4-yl aminobenzoic acid derivatives (<b>6a-c</b>, <b>7a-c</b>, and <b>8a-c</b>) as new non-classical CA inhibitors. On account of its significance in the anticancer drug discovery and in the development of effective CAIs, the 4-anilinoquinazoline privileged scaffold was exploited  ...[more]

Similar Datasets

| S-EPMC5601383 | biostudies-literature
| S-EPMC10707797 | biostudies-literature
| S-EPMC9822402 | biostudies-literature
| S-EPMC10258898 | biostudies-literature
| S-EPMC6928609 | biostudies-literature
| S-EPMC9090362 | biostudies-literature
| S-EPMC5943959 | biostudies-literature
| S-EPMC6142056 | biostudies-literature
| S-EPMC10035951 | biostudies-literature
| S-EPMC8973350 | biostudies-literature